AbCellera And Lilly Expand Collaboration To Develop Antibody Medicines
Portfolio Pulse from Benzinga Newsdesk
AbCellera (NASDAQ:ABCL) and Eli Lilly (NYSE:LLY) have expanded their collaboration to develop therapeutic antibodies for immunology, cardiovascular disease, and neuroscience. This builds on their successful partnership since March 2020, which included eight de novo programs and a COVID-19 antibody program that received emergency use authorization from the FDA.
July 31, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbCellera has expanded its collaboration with Eli Lilly to develop therapeutic antibodies for various diseases, building on a successful partnership that included FDA-authorized COVID-19 therapies.
The expanded collaboration with Eli Lilly is likely to positively impact AbCellera's stock price in the short term due to the potential for new therapeutic developments and the success of their previous partnership.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Eli Lilly has expanded its collaboration with AbCellera to develop therapeutic antibodies for various diseases, building on a successful partnership that included FDA-authorized COVID-19 therapies.
The expanded collaboration with AbCellera is likely to positively impact Eli Lilly's stock price in the short term due to the potential for new therapeutic developments and the success of their previous partnership.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 80